| Impact Physical Therapy, Llc | |
|
485 Clinton Ct, Amherst, WI 54406-9203 | |
| (715) 824-4460 | |
| (715) 824-3278 |
| Full Name | Impact Physical Therapy, Llc |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 485 Clinton Ct, Amherst, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871066233 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Diane Fletcher Klos |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609871508 PECOS PAC ID: 5193626422 Enrollment ID: I20040119000528 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Provider Name | Hanni R Cowley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013902402 PECOS PAC ID: 2062449127 Enrollment ID: I20050720000407 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Provider Name | Matthew D Haberl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366693285 PECOS PAC ID: 8426238932 Enrollment ID: I20110215000620 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Provider Name | Jacob Martin Hegge |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1598201980 PECOS PAC ID: 1254615784 Enrollment ID: I20170301002116 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Provider Name | Marci Jean Skemp |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740541846 PECOS PAC ID: 1456508498 Enrollment ID: I20180201002040 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Provider Name | Michael J Borst |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1235517046 PECOS PAC ID: 2860740529 Enrollment ID: I20180813001567 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Impact Physical Therapy, Llc Po Box 324, Amherst, WI 54406-0324 Ph: (715) 529-3487 | Impact Physical Therapy, Llc 485 Clinton Ct, Amherst, WI 54406-9203 Ph: (715) 824-4460 |
News Archive
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
This International Women's Day, March 8, 2010, ONE will launch Women ONE2ONE, a major new campaign designed to save lives and increase opportunities for women who live in extreme poverty.
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.
› Verified 8 days ago
Jacob J Brenner Iii, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 167 N Main St, Amherst, WI 54406 Phone: 715-529-3424 Fax: 715-251-6236 | |
Mr. Brett Roberts, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 167 N Main St, Amherst, WI 54406 Phone: 715-529-3487 Fax: 715-251-6236 | |
Nathan Brown, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 167 N Main St, Amherst, WI 54406 Phone: 715-529-3787 Fax: 715-251-6236 |